Thus, to obtain cells before and after disease progression with the same genetic background (harbouring mutations in RUNX1 and SRSF2), and to understand the contribution of mutations disrupting the C/EBPα bZIP domain to the disease progression, we applied CRISPR-Cas9 technology to introduce a CEBPA mid-region mutation disrupting the bZIP domain into the MDS27-C22 hiPSCs generated (hereafter, CEBPAbZIP-fs), mimicking the disruption of the bZIP domain observed in the MDS patient. The gene discussed is CEBPA; the disease is myelodysplastic syndrome.